Cipher Pharmaceuticals Inc. (TSE:CPH - Get Free Report) NASDAQ: CPHR's share price crossed below its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of C$12.81 and traded as low as C$12.81. Cipher Pharmaceuticals shares last traded at C$12.86, with a volume of 23,771 shares.
Analysts Set New Price Targets
Separately, Canaccord Genuity Group set a C$12.50 target price on shares of Cipher Pharmaceuticals and gave the company a "hold" rating in a research note on Monday, April 7th.
Check Out Our Latest Stock Report on CPH
Cipher Pharmaceuticals Stock Down 1.8%
The company has a debt-to-equity ratio of 41.22, a current ratio of 2.00 and a quick ratio of 2.67. The firm has a market capitalization of C$225.13 million, a P/E ratio of 13.85 and a beta of 1.20. The business has a 50 day moving average price of C$12.85 and a 200 day moving average price of C$12.96.
About Cipher Pharmaceuticals
(
Get Free Report)
Cipher Pharmaceuticals Inc is a specialty pharmaceutical company. Its products include Dermatology Products, Hospital Acute Care Products, and Out-Licensed Products among others. The company's geographical segments include Canada and the United States.
Further Reading
Before you consider Cipher Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cipher Pharmaceuticals wasn't on the list.
While Cipher Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
